Cabozantinib

The combination of cabozantinib and nivolumab showed promising efficacy for certain patients with metastatic non-clear cell renal cell carcinoma, according to phase 2 study results presented at International Kidney Cancer Symposium.

Recent data revealed the Right to Try track did not more successfully help oncologists obtain investigational drugs than Expanded Access, which has an extra step of receiving FDA authorization for each patient.

The FDA granted priority review to cabozantinib for treatment of certain patients with differentiated thyroid cancer.

The combination of cabozantinib and atezolizumab prolonged PFS compared with sorafenib among patients with previously untreated advanced hepatocellular carcinoma, according to topline data released by one of the agent’s manufacturers.

The FDA granted breakthrough therapy designation to cabozantinib for treatment of certain patients with thyroid cancer, according to the agent’s manufacturer.

Cabozantinib conferred a significant and meaningful extension of PFS compared with sunitinib in metastatic papillary renal cell carcinoma, according to results of a phase 2 randomized trial presented at Genitourinary Cancers Symposium.

The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.

The FDA granted priority review to nivolumab in combination with cabozantinib for treatment of advanced renal cell carcinoma.

Nivolumab plus cabozantinib conferred superior PFS, OS and response rates compared with sunitinib as a first-line treatment for advanced renal cell carcinoma, according to results of a phase 3 study presented at ESMO Virtual Congress 2020.

Selpercatinib appeared to be effective and safe for patients with RET-altered medullary thyroid cancer and RET fusion-positive non-small cell lung cancer, according to results of two studies published in The New England Journal of Medicine.